POMDOCTOR LIMITED Announces Receipt of Nasdaq Staff Delisting Determination
POMDOCTOR LIMITED (Nasdaq: POM) received a delisting notice from Nasdaq due to its ADS price falling below $1.00 for 30 consecutive days. The company is ineligible for a compliance period due to a recent reverse stock split. POM plans to appeal the decision by October 13, 2026, to avoid suspension and delisting.
How this was made
The 30-second read
Why it matters
The staff determination creates an imminent risk of suspension and delisting, which could erode market confidence and liquidity. The outcome hinges on the company's appeal and any remedial plan it presents.
Market read
The news directly affects POM's share price and may influence investor sentiment toward other low‑price Nasdaq stocks.
What to watch
Potential for a private placement or alternative financing to support a relisting, and the effect of broader market sentiment on low‑float stocks.
Background
POMDoctor Limited is a digital healthcare firm listed on Nasdaq under ticker POM. The company executed a 1‑for‑18 reverse split on June 22, 2026, and its share price fell below $1 for 30 consecutive days, triggering Nasdaq's delisting rules.
Ticker impact
Nasdaq staff determined POM's shares will be delisted due to bid price below $1 and a recent reverse split, with suspension effective Oct 15 unless appealed.
likely downward pressure as investors anticipate trading suspension and possible loss of listing.
The delisting determination is a concrete regulatory action that can immediately affect liquidity and valuation.
Market effects
May signal heightened scrutiny for other low‑price Nasdaq listings, especially those that have recently executed reverse splits.
Limited to U.S. equity markets; Chinese‑listed investors may face additional regulatory considerations.
Minimal global impact beyond the specific ticker.
Counterpoint
If the company successfully appeals and regains compliance, the stock could rebound sharply from oversold levels.
Key entities
- CompanyPOMDoctor Limited
Nasdaq‑listed digital healthcare company facing delisting.
- Regulatory BodyNasdaq Listing Qualifications Department
Issued the delisting determination.
